Compare PPTA & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPTA | STVN |
|---|---|---|
| Founded | 2011 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Precious Metals | Containers/Packaging |
| Sector | Basic Materials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 2011 | 2021 |
| Metric | PPTA | STVN |
|---|---|---|
| Price | $21.33 | $19.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $37.38 | $25.67 |
| AVG Volume (30 Days) | ★ 2.1M | 371.6K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.39% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.67 |
| Revenue Next Year | N/A | $9.99 |
| P/E Ratio | ★ N/A | $27.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.21 | $12.89 |
| 52 Week High | $37.37 | $28.00 |
| Indicator | PPTA | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 38.85 | 61.94 |
| Support Level | $20.74 | $13.58 |
| Resistance Level | $26.23 | $19.41 |
| Average True Range (ATR) | 1.30 | 0.88 |
| MACD | -0.10 | 0.14 |
| Stochastic Oscillator | 20.25 | 99.27 |
Perpetua Resources Corp is engaged in acquiring mining properties with the intention of exploring, evaluating, developing and placing them into production, if warranted. Its principal mineral project is the Stibnite Gold Project in Idaho, USA, which contains several gold, silver and antimony mineral deposits. The company's current focus is to redevelop three of the Deposits known as the Hangar Flats Deposit, West End Deposit and Yellow Pine Deposit, all of which are located within the Stibnite Gold Project, as well as reprocess certain historical tailings located on the Project. It operates in one segment: mineral exploration and development in the United States.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.